ACA App
Annals of Cardiac Anaesthesia Annals of Cardiac Anaesthesia Annals of Cardiac Anaesthesia
Home | About us | Editorial Board | Search | Ahead of print | Current Issue | Archives | Submission | Subscribe | Advertise | Contact | Login 
Users online: 664 Small font size Default font size Increase font size Print this article Email this article Bookmark this page
 


 

 
     
    Advanced search
 

 
 
     
  
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Email Alert *
    Add to My List *
* Registration required (free)  


    Abstract
    Introduction
    Materials and Me...
    Results
    Discussion
    Conclusion
    References
    Article Tables

 Article Access Statistics
    Viewed6680    
    Printed271    
    Emailed3    
    PDF Downloaded1124    
    Comments [Add]    
    Cited by others 14    

Recommend this journal

 


 
ORIGINAL ARTICLE Table of Contents   
Year : 2008  |  Volume : 11  |  Issue : 1  |  Page : 20-26
Resistance in gram-negative bacilli in a cardiac intensive care unit in India: Risk factors and outcome


1 Escorts Heart Institute and Research Centre, New Delhi, India
2 Indraprastha Apollo Hospital, New Delhi, India
3 Medical College of Buenos Aires, Argentina

Click here for correspondence address and email
 

   Abstract 

The objective of this study was to compare the risk factors and outcome of patients with preexisting resistant gram-negative bacilli (GNB) with those who develop sensitive GNB in the cardiac intensive care unit (ICU). Of the 3161 patients ( n = 3,161) admitted to the ICU during the study period, 130 (4.11%) developed health care-associated infections (HAIs) with GNB and were included in the cohort study. Pseudomonas aeruginosa (37.8%) was the most common organism isolated followed by Klebsiella species (24.2%), E. coli (22.0%), Enterobacter species (6.1%), Stenotrophomonas maltophilia (5.7%), Acinetobacter species (1.3%), Serratia marcescens (0.8%), Weeksella virosa (0.4%) and Burkholderia cepacia (0.4%). Univariate analysis revealed that the following variables were significantly associated with the antibiotic-resistant GNB: females ( P = 0.018), re-exploration ( P = 0.004), valve surgery ( P = 0.003), duration of central venous catheter ( P < 0.001), duration of mechanical ventilation ( P < 0.001), duration of intra-aortic balloon counter-pulsation ( P = 0.018), duration of urinary catheter ( P < 0.001), total number of antibiotic exposures prior to the development of resistance ( P < 0.001), duration of antibiotic use prior to the development of resistance ( P = 0.014), acute physiology and age chronic health evaluation score (APACHE II), receipt of anti-pseudomonal penicillins (piperacillin-tazobactam) ( P = 0.002) and carbapenems ( P < 0.001). On multivariate analysis, valve surgery (adjusted OR = 2.033; 95% CI = 1.052-3.928; P = 0.035), duration of mechanical ventilation (adjusted OR = 1.265; 95% CI = 1.055-1.517; P = 0.011) and total number of antibiotic exposure prior to the development of resistance (adjusted OR = 1.381; 95% CI = 1.030-1.853; P = 0.031) were identified as independent risk factors for HAIs in resistant GNB. The mortality rate in patients with resistant GNB was significantly higher than those with sensitive GNB (13.9% vs. 1.8%; P = 0.03). HAI with resistant GNB, in ICU following cardiac surgery, are independently associated with the following variables: valve surgeries, duration of mechanical ventilation and prior exposure to antibiotics. The mortality rate is significantly higher among patients with resistant GNB.

Keywords: Cardiac surgery, gram-negative bacilli, intensive care unit, nosocomial infection, resistance

How to cite this article:
Pawar M, Mehta Y, Purohit A, Trehan N, Daniel RV. Resistance in gram-negative bacilli in a cardiac intensive care unit in India: Risk factors and outcome. Ann Card Anaesth 2008;11:20-6

How to cite this URL:
Pawar M, Mehta Y, Purohit A, Trehan N, Daniel RV. Resistance in gram-negative bacilli in a cardiac intensive care unit in India: Risk factors and outcome. Ann Card Anaesth [serial online] 2008 [cited 2019 Jun 15];11:20-6. Available from: http://www.annals.in/text.asp?2008/11/1/20/38445



   Introduction Top


Antibiotic-resistant organisms are the common causative organisms of health care-associated infections (HAIs), particularly in the intensive care unit (ICU) setting. [1] Over the past several decades, the frequency of antimicrobial resistance and its association with serious infectious diseases have increased at alarming rates. [2] The increasing resistance rate among the nosocomial pathogens is particularly disconcerting. This high rate of resistance increases the morbidity, mortality and the costs concerned with the HAIs. [3],[4]

Extensive antibiotic resistance has been observed in GNB, due to both innate resistance in some species and the fact that they are highly adept at acquiring antibiotic-resistant determinants from each other. Antibiotic resistance develops through different mechanisms, including the alteration of the drug target, prevention of drug access to the target (including active elimination of the drug from the bacteria) and drug inactivation. [5]

A study conducted in India has identified the risk factors associated with infection by antibiotic-resistant pathogens in the ICU; [6] however, none has analyzed these factors in cardiac surgical ICU. We therefore conducted a prospective study to compare the risk factors and outcome between patients with resistant GNB and those who develop sensitive GNB in the cardiac surgical ICU.


   Materials and Methods Top


Between July 2004 and January 2005, 3161 patients were admitted to the cardiac surgical ICU. Patients who developed HAI with GNB within 48 h of admission to the ICU were enrolled in the study. This study was approved from the institutional review board, and informed consent obtained from the patients for this prospective study.

Definitions

HAIs (urinary tract infection, blood stream infection and surgical site infections) were defined according to the criteria established by the Centers for Disease Control and Prevention (CDC). [7] HAIs were required to be established within 48 h after admission to the surgical ICU. The diagnostic criteria for ventilator-associated pneumonia (VAP) were modified from those established by the American College of Chest Physicians. [8] VAP was prospectively defined as the occurrence of a new and persistent radiographic infiltrate in conjunction with one of the following: positive pleural/blood culture findings for the same organism as that recovered in the tracheal aspirate or sputum; radiographic cavitation; histopathological evidence of pneumonia; or any two from fever, leukocytosis and purulent tracheal aspirate or sputum.

Persistence of an infiltrate was defined as persistence of radiographic infiltrates for at least 72 h. Fever was defined as an increase in the core temperature of ≥1 o C and the core temperature was >38.3 o C. Leukocytosis was defined as a 25% increase in the number of circulating leukocytes from the baseline and a value of >10 × 10 9 /litre. Tracheal aspirate was considered purulent if abundant neutrophils were present per high power field using Gram Stain (i.e., >25 neutrophils per high power field). Tracheal aspiration and/or bronchoscopic or aspiration lavage cultures were obtained at the time when the diagnosis of VAP was being considered.

APACHE II score was calculated on the basis of the clinical data available in the first 24 h in the ICU. [10] Hospital mortality was defined as death occurring within 30 days of admission to the ICU. Prophylactic antimicrobial treatment was defined as any antibiotic administered parenterally in the perioperative period for the prevention of infection resulting from the surgical procedure. All other antimicrobial administrations in the ICU were classified as either empirical or infection-directed treatment. Previous antimicrobial use was defined as the intravenous antimicrobial administration for more than 24 h prior to the isolation of the resistant organism. Antibiotic resistance was defined as resistance to at least two of the following antibiotics: piperacillin-tazobactam, ceftazidime, amikacin and imipenem.

Study design and data collection

A prospective observational study was conducted, segregating the patients having HAIs with resistant and sensitive GNB (group 1 and group 2, respectively) 48 h after admission to the surgical ICU. The 30-day hospital mortality was evaluated and other secondary outcomes were also assessed, including the length of stay in the ICU and hospital, duration of mechanical ventilation (MV), intra-aortic balloon counterpulsation (IABC), urinary catheter and central venous catheters (CVC).

The following characteristics were prospectively recorded for all patients at the beginning of the study: age; sex; type of surgery (elective/emergency); reexploration; underlying comorbid conditions such as obesity (BMI >30), diabetes, chronic obstructive pulmonary disease (COPD), bronchial asthma, duration of CVC, IABC, MV and urinary catheterization; total number and group of administration of antibiotics prior to the development of resistance that included the use of prophylactic antibiotics. The first and second lines of empirical antibiotics were used when infection was suspected as well as when the use of antibiotics was based on the confirmed patterns of culture and sensitivity. The duration of antibiotic use prior to the development of resistance, severity of illness based on acute physiology and chronic health evaluation (APACHE II) score, total length of stay in ICU and hospital, total length of stay in hospital before surgery and before the development of resistance.

Patients received intravenous antibiotic prophylaxis of cefazolin 1 g twice a day and amikacin 15 mg/kg once a day for 24 h.

One of the researchers made daily rounds on all study patients, recording relevant data from the medical records, bedside flow-sheets and the mainframe computer of the hospital for microbiological reports. The patients enrolled in the study were prospectively followed-up until discharged from the ICU/ward or died.

Appropriate culture samples were obtained as clinically indicated by the patients' primary care physician. Species identification and antimicrobial susceptibility testing were performed using the min-API system (Bio-Merieux, Lyon, France). The antibiotics tested were amoxicillin, amoxicillin-clavulanic acid, ticarcillin, ticarcillin-clavulanic acid, piperacillin, piperacillin-tazobactam, cefalotin, cefoxitin, cefotaxime, ceftazidime, cefpirome, cefepime, imipenem, aztreonam, tobramycin, amikacin, gentamicin, netilmycin, ciprofloxacin, cotrimoxazole, meropenem and cefoperazone-sulbactam.

Statistical analysis

All comparisons were unpaired and all tests of significance were two-tailed. Continuous variables were compared using the 'student's t test' for normally distributed variables and the Wilcoxon rank sum test for non-normally distributed variables. The Chi square or Fisher's Exact test was used to compare categorical variables. The primary data analysis was used to compare patients who acquired resistant GNB HAI and those who developed sensitive GNB HAI. Multiple logistic regression analysis was used to identify the independent risk factors for resistant GNB HAI.

A stepwise approach was used to introduce new terms into the logistic regression models where 0.05 was set as the limit for the acceptance or removal of new terms. Model overfitting was examined by evaluating the ratio of outcome events to the total number of independent variables in the final models. The interactions between the independent variables were included in the analyses. [9] Results of the logistic regression analyses were reported as adjusted odds ratios (AOR) with 95% confidence intervals (CIs). Relative risk and their 95% CIs were calculated using the standard methods. Values are expressed as mean ± SD (continuous variables) or as a percentage of the group from which they were derived (categorical variables). All P values were two-tailed; P values of ≤0.05 were considered statistically significant. Statistical analysis was carried out by using SPSS version 13.0.


   Results Top


0Of the 3,161 patients admitted to the ICU during the study period, 130 (4.11%) developed HAI with GNB and were included in the study cohort. The mean age of the patient was 58.08 ± 11.67 years (range, 12-88 years) and the mean APACHE II score of the study cohort was 9.71 ± 3.38 (range, 3-20). Of the 130 patients, 32 (24%) were females [Table - 1].

During the study period, 227 clinically significant GNB isolates were collected from 130 patients. Overall VAP (72.7%) was the most common infection followed by urinary tract infection (15.2%), blood stream infection (5.2%), surgical site infection (1.6%) and other infections (5.2%). There were no significant differences in the distribution sites between resistant and sensitive GNB.

Pseudomonas aeruginosa (37.8%) was the most common organism isolated followed by Klebsiella species (24.2%), E. coli (22.0%), Enterobacter species (6.1%), Stenotrophomonas maltophilia (5.7%), Acinetobacter species (1.3%), Serratia marcescens (0.8%), Weeksella virosa (0.4%) and Burkholderia cepacia (0.4%). Imipenem (95.76%), meropenem (82.56%) and amikacin (71.6%) showed best activity against E. coli , Klebsiella species, Enterobacter species and S. marcescens . Of these isolates, 65% were susceptible to piperacillin-tazobactam. P. aeruginosa were less susceptible to imipenem (40%), piperacillin-tazobactam (40.2%), meropenem (39.5%) and amikacin (22.3%). S. maltophilia was resistant to imipenem, meropenem, amikacin and piperacillin-tazobactam and showed poor susceptibility to ceftazidime (46%), ciprofloxacin (46.1%), cefoperazone-sulbactam (30.7%) and ticarcillin-clavulanic acid (30.7%). Acinetobacter species showed 100% susceptibility to amikacin and 80% susceptibility to imipenem, piperacillin-tazobactam, meropenem, cefoperazone-sulbactam, piperacillin, ceftazidime, cefepime and ciprofloxacin [Table - 2].

Univariate analysis showed that female gender (P = 0.018), re-exploration (P = 0.004), valve surgery (P = 0.003), duration of CVC (P < 0.001), MV (P < 0.001), IABC (P = 0.018) and presence of urinary catheter (P < 0.001), the number of antibiotics administered prior to the development of resistance (P < 0.001), duration of antibiotic exposure prior to the development of resistance (P = 0.014), receipt of antipseudomonal penicillins (piperacillin-tazobactam) (P = 0.002) and carbapenems (P < 0.001). APACHE II scores were significantly associated with group 1 (resistant GNB). Length of stay in hospital prior to surgery (P = 0.044), total length of stay in the ICU (P < 0.001), total length of stay in the hospital prior to the development of resistance (P = 0.004) and total stay in the hospital (P ≤ 0.001) were significantly higher in group 1 than in group 2. Mortality rate was significantly higher in group 1 as compared with group 2 (13.9% vs. 1.8%; P = 0.013) [Table - 3].

Multivariate analysis showed that valve surgery AOR = 2.033; 95%CI = 1.052-3.928; p = 0.035; duration of MV (AOR = 1.265; 95%CI = 1.055-1.517; p = 0.011) and receipt of total number of antibiotics before the development of resistance (AOR = 1.381; 95% CI = 1.030-1.853; p = 0.031) were independent risk factors in the development of resistant GNB HAI (group 1).


   Discussion Top


Infections caused by multidrug-resistant bacteria constitute a serious problem in critically ill patients in the ICU all over the world. [3],[11],[12] Resistance to antimicrobial agents is an increasing clinical complication and is recognized as a threat to public health in developed and developing countries. [13],[14],[15],[16],[17] These resistant HAIs can have tremendous financial impact on a system with limited resources. [18],[19],[20]

In this study, we found that mortality was significantly higher in patients with antibiotic-resistant GNB infections. Infections due to antibiotic-resistant bacterial strains are generally more severe in critically ill patients and a greater morbidity and mortality can be expected in them. Some antibiotic-resistant gram-negative bacteria are associated with more virulent factors than antibiotic-susceptible pathogens, which may also explain some of the excess attributable mortality rates observed in patients infected with these pathogens. [21],[22],[23],[24],[25]

Some investigators have reported that in general, the prognosis from the infections caused by resistant organisms is poor. Worsened prognosis may relate to the severity of illness to the extent that inadequate therapy may be responsible for increased mortality. Resistance is probably a factor that directly contributes to a poor outcome through the mechanism of persistent and unresolving infectious insult. [26]

In our study, prior administration of antibiotics such as piperacillin-tazobactam and carbopenems, (prior to the development of resistance) was observed to significantly increase the likelihood of the development of antibiotic resistance. Prior administration of antibiotic itself was an independent predictor of the occurrence of resistant GNB infection. Misuse of antibiotics (which are active against a wide spectrum of organisms) may be one of the reasons for the development of resistant varieties of microbial organisms. The use of such antibiotics also increases the overall cost of antimicrobial therapy.

Appropriate use of antibiotics is life saving in patients with severe HAIs; however, their inappropriate use must be restricted. Moreover, clinicians should balance the need to provide an adequate antimicrobial protection to infected patients while considering the risks of antibiotic misuse - predisposing to the subsequent emergence of antibiotic-resistant infections. A potential strategy for balancing these two competing issues would involve early administration of broad-spectrum antimicrobial treatment to high risk patients with suspected HAIs. This should be followed by rapid de-escalation of the antimicrobial regimen or discontinuation of antimicrobial treatment on the basis of the culture results and the clinical course of the patient. [27]

In patients with resistant infections, the duration of antibiotic administration is found to be significantly higher. Robert Muder et al., [28] have shown that the total number of days of exposure to antibiotics was correlated significantly with multiple resistance in P. aeruginosa . Prolonged exposure to these diverse antibiotics may have reduced the populations of endogenous flora in the patients facilitating the acquisition of the resistant P. aeruginosa .

P. aeruginosa is the leading cause of HAIs, which rank second among the gram-negative pathogens reported to the National Nosocomial Infection Surveillance system. [29] There are limited numbers of antimicrobial agents with reliable activity against P. aeruginosa , including antipseudomonal penicillins and cephalosporins, carbopenems and fluoroquinolones, particularly ciprofloxacin. Aminoglycosides are frequently used as a part of combination regimens for the treatment of serious pseudomonal infections, but are generally not recommended as single-drug regimen. [29] It is intrinsically resistant to various antibiotics at concentrations achievable in vivo. Under selective antibiotic pressure it has proven to be particularly capable of acquiring antibiotic resistance both by chromosomal-mediated and plasmid acquired mechanisms.

The significantly higher use of carbapenem and antipseudomonal antibiotics may explain the subsequent development of resistant P. aeruginosa in our study. Widespread use of carbapenem antibiotics has allowed the increase in other nosocomial pathogen such as S. maltophilia . [30],[31] Patients receiving carbapenems, particularly those on MV, are at an increased risk of colonization or infection with class B metallo-enzyme producers such as S. maltophilia . [30] Indeed, with the increased use of carbapenems, more strains of S. maltophilia were isolated compared to the earlier study conducted at the same institution. [32] The combination of high innate antibiotic resistance and selective antibiotic pressure has resulted in the emergence of pathogens such as S. maltophilia as important nosocomial pathogens. [33],[34] As studied by Gunten and colleagues, the most common gram-negative organisms identified in this study were P. aeruginosa , Klebsiella species and E. coli . [35] In this study, the incidence of urinary tract infection was significantly higher in the group that developed resistant GNB. Female gender was identified as an independent risk factor for infection with resistant GNB. Previous studies have shown that female gender, due to anatomical predisposition, may be associated with an increased incidence of wound and urinary tract infection. [36],[37]

The prolonged presence of invasive devices such as endotracheal tube, intravascular catheter and urinary catheter has been associated with the emergence of antibiotic resistance. [13],[14],[15],[16],[17] These devices are frequently associated with the formation of biofilms on their surfaces. Antibiotic penetration into biofilms is usually diminished, allowing sequestered pathogens colonizing these devices within the biofilms to be exposed to subtherapeutic concentration of antimicrobial agents; further, the presence of such environment favours the emergence of antibiotic resistant microorganisms. [38] This explains the significantly higher infection rates in patients in whom the invasive devices are retained for longer duration. The MV for ≥ 7 days was independently associated with the development of VAP due to antibiotic-resistant pathogens. [39] In this study, multivariate logistic regression analysis duration of MV was an independent predictor of GNB-resistant infections.

Valve surgery was independently associated with antibiotic-resistant infections. We observed that the number of administrations of antibiotics prior to the development of resistance was significantly higher in the cohorts with resistant organisms. Compromised host resistance might be more significant in patients with valvular heart disease. [40]

By univariate analysis, surgical reexploration was observed to be significantly higher in patients with resistant-GNB infections. This may be because a second surgery increases the risk by a longer surgical time, possible increased requirement of transfusion of blood and blood products, tissue trauma, inadvertent contamination during emergencies. Usually patients requiring reexploration are critically ill. [41]

Antibiotic resistance is more common in patients who have a prolonged stay in ICU, but this is not the only cause of development of antibiotic resistance. [42] In 1995, in Boston, the examination of cultures obtained from patients within 24 h of admission to the ICUs revealed that 18% of patients were colonized with ceftazidime-resistant GNB. [42] These colonized patients were more likely to have been admitted in a hospital in the previous 12 months and had longer hospitalisation prior to ICU admission. Extended stay in hospitals appears to predispose the patients to infection with antibiotic-resistant bacteria. [39] This may be partly due to the greater likelihood of patients becoming colonized with such bacteria, from either horizontal nosocomial transmission or endogenous emergence of resistance, if the patient remains in hospital for prolonged duration. [43] We found that the hospital stay before surgery, ICU stay before the development of resistance and total hospital stay were significantly higher in antibiotic-resistant population.


   Conclusion Top


In conclusion, we found that the duration of MV, valve surgery and the total number of antibiotics received by the patient are significant predictors for the development of resistant GNB. Given the increasing rates of HAI due to antibiotic-resistant bacteria, clinicians should consider the risk factors for identifying the patients at risk, including prior antibiotic treatment, operative procedures and the duration of invasive devices. The previous use of carbopenems and antipseudomonal penicillins was associated with the development of resistant GNB HAIs; therefore, their use should be restricted.

 
   References Top

1.Niederman MS. Impact of antibiotic resistance on clinical outcomes and the cost of care. Crit Care Med 2001;29:N114-20.  Back to cited text no. 1  [PUBMED]  [FULLTEXT]
2.Jones RN. Resistance patterns among nosocomial pathogens. Chest 2001;119:397s-404s.   Back to cited text no. 2  [PUBMED]  [FULLTEXT]
3.Emori TG, Gaynes RP. An overview of nosocomial infections, including the role of the microbiology laboratory. Clin Microbiol Rev 1993;6:428-42.  Back to cited text no. 3  [PUBMED]  [FULLTEXT]
4.Jones RN, Kehrberg EN, Erwin ME, Anderson SC. Prevalence of important pathogens and antimicrobial activity of parenteral drugs at numerous medical centers in the United States, I: Study on the threat of emerging resistances: Real or perceived? Fluoroquinolone Resistance Surveillance Group. Diagn Microbiol Infect Dis 1994;19:203-15.  Back to cited text no. 4    
5.Waterer GW, Wunderink RG. Increasing threat of Gram-negative bacteria. Crit Care Med 2001;29:N75-81.  Back to cited text no. 5  [PUBMED]  [FULLTEXT]
6.Merchant M, Karnard DR, Kanbur AA. Incidence of nosocomial pneumonia in a medical intensive care: Unit and general medical ward patients in a public hospital in Mumbai, India. J Hosp Infect 1998;39:143-8.  Back to cited text no. 6    
7.Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections. Am J Infect Control 1988;16:128-40.  Back to cited text no. 7  [PUBMED]  [FULLTEXT]
8.Pingleton SK, Fagon JY, Leeper KV Jr. Patient selection for clinical investigation of ventilator-associated pneumonia: Criteria for evaluating diagnostic techniques. Chest 1992;102:553S-6S.  Back to cited text no. 8  [PUBMED]  
9.Concato J, Feinstein AR, Holford TR. The risk of determining risk with multivariable models. Ann Intern Med 1993;118:201-10.  Back to cited text no. 9  [PUBMED]  [FULLTEXT]
10.Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: A severity of diseases classification system. Crit Care Med 1985;13:818-29.  Back to cited text no. 10  [PUBMED]  
11.Verbist L. Epidemiology and sensitivity of 8625 ICU and hematology/oncology bacterial isolates in Europe. Scand J Infect Dis Suppl 1993;91:14-24.  Back to cited text no. 11  [PUBMED]  
12.George DL. Epidemiology of nosocomial ventilator-associated pneumonia. Infect Control Hosp Epidemiol 1993;14:163-9.  Back to cited text no. 12  [PUBMED]  
13.Rosenthal VD, Maki DG, Salomao R, Moreno CA, Mehta Y, Higuera F, et al. Device-Associated Nosocomial Infections in 55 Intensive Care Units of Eight Developing Countries: Findings of an International Nosocomial Infection Control Consortium. Ann Int Med 2006;145:582-91.  Back to cited text no. 13  [PUBMED]  [FULLTEXT]
14.Moreno CA, Rosenthal VD, Olarte N, Gomez WV, Sussmann O, Agudelo JG, et al. Device-associated infection rate and mortality in intensive care units of 9 colombian hospitals: Findings of the international nosocomial infection control consortium. Infect Control Hosp Epidemiol 2006;27:349-56.  Back to cited text no. 14  [PUBMED]  [FULLTEXT]
15.Ramirez Barba EJ, Rosenthal VD, Higuera F, Oropeza MS, Hernàndez HT, Lòpez MS, et al. Device-associated nosocomial infection rates in intensive care units in four Mexican public hospitals. Am J Infect Control 2006;34:244-7.  Back to cited text no. 15    
16.Rosenthal VD, Guzman S, Crnich C. Device-associated nosocomial infection rates in intensive care units of Argentina. Infect Control Hosp Epidemiol 2004;25:251-5.  Back to cited text no. 16    
17.Rosenthal VD, Guzman S, Orellano PW, Safdar N. Nosocomial infections in medical-surgical intensive care units in Argentina: Attributable mortality and length of stay. Am J Infect Control 2003;31:291-5.  Back to cited text no. 17    
18.Higuera F, Rangel-Frausto MS, Rosenthal VD, Soto JM, Castaρon J, Franco G, et al. The Attributable Cost and length of stay for patients with central venous catheter-Associated Blood Stream Infection in Mexico City Intensive Care Units: A Prospective, Matched Analysis. Infect Control Hosp Epidemiol 2007;28:31-5.  Back to cited text no. 18    
19.Rosenthal VD, Guzman S, Migone O, Safdar N. The attributable cost and length of hospital stay because of nosocomial pneumonia in intensive care units in 3 hospitals in Argentina: A prospective, matched analysis. Am J Infect Control 2005;33:157-61.  Back to cited text no. 19  [PUBMED]  [FULLTEXT]
20.Rosenthal VD, Guzman S, Migone O, Crnich CJ. The attributable cost, length of hospital stay and mortality of central line-associated bloodstream infection in intensive care departments in Argentina: A prospective, matched analysis. Am J Infect Control 2003;31:475-80.  Back to cited text no. 20  [PUBMED]  [FULLTEXT]
21.Rello J, Ausian V, Ricart M, Castella J, Prats G. Impact of previous antimicrobial therapy on the etiology and outcome of ventilator associated pneumonia. Chest 1993;104:1230-5.  Back to cited text no. 21    
22.Van Delden C, Iglewski BH. Cell to cell singlaling and Pseudomonas aeruginosa infections. Emerg Infect Dis 1998;4:551-60.  Back to cited text no. 22  [PUBMED]  [FULLTEXT]
23.Denton M, Kerr MG. Microbiological and clinical aspects of infection associated with stenotophomonas maltophilia. Clin Microbiol Rev 1998;11:57-80.  Back to cited text no. 23    
24.Fagon JY, Chastre J, Hance AJ, Montravers P, Novara A, Gibert C. Nosocomial pneumonia in ventilated patients: A cohort study evaluating attributable mortality and hospital stay. Am J Med 1993;94:281-8.  Back to cited text no. 24  [PUBMED]  [FULLTEXT]
25.Heyland DK, Cook DJ, Griffith L, Keenan SP, Brun-Buisson C. The attributable morbidity and mortality of ventilator associated pneumonia in the critically ill patients. Am J Respir Crit Care Med 1999;159:1249-56.  Back to cited text no. 25  [PUBMED]  [FULLTEXT]
26.Niederman MS. Impact of antiobiotic resistance on clinical outcomes and the cost of care. Crit Care Med 2001;29:N114-20.  Back to cited text no. 26  [PUBMED]  [FULLTEXT]
27.Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH. The influence of inadequqte antimicrobial treatment of bloodstream infections on patient outcome in the ICU setting. Chest 2007;118:146-55.   Back to cited text no. 27    
28.Muder RR, Brennen C, Drenning SD, Stout JE, Wagener MM. Multiply antibiotic-resistant gram-negative bacilli in a long-term-care facility: A case-control study of patient risk factors and prior antibiotic use. Infect Control Hosp Epidemiol 1997;18:809-13.  Back to cited text no. 28  [PUBMED]  
29.Carmeli Y, Troillet N, Eliopoulos GM, Samore MH. Emegence of antibiotic resistant pseudomonas aeruginosa: Comparison of risk associated with different antipseudomonal agents. Antimicrobial agents and chemotherapy 1999;43:1379-82.  Back to cited text no. 29  [PUBMED]  [FULLTEXT]
30.Livermore DM. beta-Lactamases in laboratory and clinical resistance. Clin Microbiol Rev 1995;8:557-84.  Back to cited text no. 30  [PUBMED]  [FULLTEXT]
31.Meyer E, Schwab F, Gastemeier P, Ryeden H, Daschner FD, Jonas D. Stenotrophomonas maltophilia and antibiotic use in German intensive care units: Data from project SARI (Surveillance of antimicrobial use and antimicrobial resistance in German intensive care units). J Hosp Infect 2006;64:238-43.   Back to cited text no. 31    
32.Pawar M, Mehta Y, Khurana P, Chaudhary A, Kulkarni V, Trehan N. Ventilator-associated pneumonia: Incidence, risk factors, outcome and microbiology. J Cardiothorac Vasc Anesth 2003;17:22-8.  Back to cited text no. 32  [PUBMED]  [FULLTEXT]
33.Marshall WF, Keating MR, Anhalt JP, Steckelberg JM. Xanthomonas maltophilia: An emerging nosocomial pathogen. Mayo Clin Proc 1989;64:1097-104.  Back to cited text no. 33  [PUBMED]  
34.Vartivarian SE, Papadakis KA, Palacios JA, Manning JT Jr, Anaissie EJ. Mucocutaneous and soft tissue infections caused by Xanthomonas maltophilia: A new spectrum. Ann Intern Med 1994;121:969-73.  Back to cited text no. 34  [PUBMED]  [FULLTEXT]
35.Von Gunten V, Reymond JP, Troillet N. Use of broad spectrum antibiotics in six non-university Swiss hospitals. Swiss Med Wkly 2001;131:29-30.   Back to cited text no. 35    
36.Kollef MH, Sharpless L, Vlasnik J, Pasque C, Murphy D, Fraser VJ. The impact of nosocomial infections on patient outcomes following cardiac surgery. Chest 1997;112:666-75.  Back to cited text no. 36  [PUBMED]  [FULLTEXT]
37.Copeland M, Senkowski C, Ergin MA, Lansman S. Macromastia as a factor in sternal wound dehiscence following cardiac surgery: Management combining chest wall reconstruction and reduction mammoplasty. J Card Surg 1992;7:275-8.  Back to cited text no. 37  [PUBMED]  
38.Coquet L, Junter GA, Jouenne T. Resistance of artificial biofilms of Pseudomonas aeruginosa to imipenem and tobramycin. J Antimicrob Chemother 1998;42:755-60.  Back to cited text no. 38  [PUBMED]  [FULLTEXT]
39.Trouillet JL, Chastre J, Vuagnat A, Joly-Guillou ML, Combaux D, Dombret MC, et al. Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am J Respir Crit Care Med 1998;157:531-9.  Back to cited text no. 39  [PUBMED]  [FULLTEXT]
40.Park SK, Brody JI, Wallace HA, Blakemore WS. Immunosuppressive effect of surgery. Lancet 1971;1:53-5.  Back to cited text no. 40  [PUBMED]  
41.Miholic J, Hudec M, Domanig E, Hiertz H, Klepetko W, Lackner F, et al. Risk factors for severe bacterial infections after valve replacement and aortocoronary bypass operations: Analysis of 246 cases by logistic regression. Ann Thorac Surg 1985;40:224-8.  Back to cited text no. 41  [PUBMED]  
42.D'Agata EM, Venkataraman L, DeGirolami P, Burke P, Eliopoulos GM, Karchmer AW, et al. Colonization with broad-spectrum cephalosporin-resistant gram-negative bacilli in intensive care units during a nonoutbreak period: Prevalence, risk factors and rate of infection. Crit Care Med 1999;27:1090-5.  Back to cited text no. 42  [PUBMED]  [FULLTEXT]
43.Kollef MH. Opinion: The clinical use of selective digestive decontamination. Crit Care 2000;4:327-32.  Back to cited text no. 43  [PUBMED]  [FULLTEXT]

Top
Correspondence Address:
Yatin Mehta
Department of Anesthesiology and Critical Care, Indraprastha Apollo Hospital, New Delhi
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0971-9784.38445

Rights and Permissions



 
 
    Tables

  [Table - 1], [Table - 2], [Table - 3]

This article has been cited by
1 International Nosocomial Infection Control Consortiu (INICC) report, data summary of 43 countries for 2007-2012. Device-associated module
Víctor Daniel Rosenthal,Dennis George Maki,Yatin Mehta,Hakan Leblebicioglu,Ziad Ahmed Memish,Haifaa Hassan Al-Mousa,Hanan Balkhy,Bijie Hu,Carlos Alvarez-Moreno,Eduardo Alexandrino Medeiros,Anucha Apisarnthanarak,Lul Raka,Luis E. Cuellar,Altaf Ahmed,Josephine Anne Navoa-Ng,Amani Ali El-Kholy,Souha Sami Kanj,Ider Bat-Erdene,Wieslawa Duszynska,Nguyen Van Truong,Leonardo N. Pazmino,Lucy Chai See-Lum,Rosalia Fernández-Hidalgo,Gabriela Di-Silvestre,Farid Zand,Sona Hlinkova,Vladislav Belskiy,Hussain Al-Rahma,Marco Tulio Luque-Torres,Nesil Bayraktar,Zan Mitrev,Vaidotas Gurskis,Dale Fisher,Ilham Bulos Abu-Khader,Kamal Berechid,Arnaldo Rodríguez-Sánchez,Florin George Horhat,Osiel Requejo-Pino,Nassya Hadjieva,Nejla Ben-Jaballah,Elías García-Mayorca,Luis Kushner-Dávalos,Srdjan Pasic,Luis E. Pedrozo-Ortiz,Eleni Apostolopoulou,Nepomuceno Mejía,May Osman Gamar-Elanbya,Kushlani Jayatilleke,Miriam de Lourdes-Dueñas,Guadalupe Aguirre-Avalos
American Journal of Infection Control. 2014; 42(9): 942
[Pubmed] | [DOI]
2 Risk Factors for Colonization due to Carbapenem-Resistant Enterobacteriaceae among Patients Exposed to Long-Term Acute Care and Acute Care Facilities
Ashish Bhargava,Kayoko Hayakawa,Ethan Silverman,Samran Haider,Krishna Chaitanya Alluri,Satya Datla,Sreelatha Diviti,Vamsi Kuchipudi,Kalyan Srinivas Muppavarapu,Paul R. Lephart,Dror Marchaim,Keith S. Kaye
Infection Control and Hospital Epidemiology. 2014; 35(4): 398
[Pubmed] | [DOI]
3 Evaluation of the potential of five medicinal plants to inhibit acyl homoserine lactone based quorum sensing in Pseudomonas aeruginosa and Acinetobacter baumannii
Gala, V. and John, N. and Desai, K.
International Journal of Pharma and Bio Sciences. 2013; 4(2): B445-B453
[Pubmed]
4 Socioeconomic impact on device-associated infections in pediatric intensive care units of 16 limited-resource countries: International Nosocomial Infection Control Consortium findings
Rosenthal, V.D. and Jarvis, W.R. and Jamulitrat, S. and Silva, C.P.R. and Ramachandran, B. and Dueñas, L. and Gurskis, V. and Ersoz, G. and Novales, M.G.M. and Khader, I.A. and Ammar, K. and Guzmán, N.B. and Navoa-Ng, J.A. and Seliem, Z.S. and Espinoza, T.A. and Meng, C.Y. and Jayatilleke, K.
Pediatric Critical Care Medicine. 2012; 13(4): 399-406
[Pubmed]
5 Socioeconomic impact on device-associated infections in pediatric intensive care units of 16 limited-resource countries
Victor D. Rosenthal,William R. Jarvis,Silom Jamulitrat,Cristiane Pavanello Rodrigues Silva,Bala Ramachandran,Lourdes Dueñas,Vaidotas Gurskis,Gulden Ersoz,María Guadalupe Miranda Novales,Ilham Abu Khader,Khaldi Ammar,Nayide Barahona Guzmán,Josephine Anne Navoa-Ng,Zeinab Salah Seliem,Teodora Atencio Espinoza,Cheong Yuet Meng,Kushlani Jayatilleke
Pediatric Critical Care Medicine. 2012; 13(4): 399
[Pubmed] | [DOI]
6 Socioeconomic impact on device-associated infections in limited-resource neonatal intensive care units: findings of the INICC
Infection. 2011;
[VIEW] | [DOI]
7 International Nosocomial Infection Control Consortium (INICC) report, data summary of 36 countries, for 2004-2009
American Journal of Infection Control. 2011;
[VIEW] | [DOI]
8 Device-associated infection rates in adult intensive care units of Cuban university hospitals: International Nosocomial Infection Control Consortium (INICC) findings
H. Guanche-Garcell, O. Requejo-Pino, V.D. Rosenthal, C. Morales-Pérez, O. Delgado-González, D. Fernández-González
International Journal of Infectious Diseases. 2011; 15(5): e357
[VIEW] | [DOI]
9 Impact of International Nosocomial Infection Control Consortium (INICC) Strategy on Central Line–Associated Bloodstream Infection Rates in the Intensive Care Units of 15 Developing Countries
Victor D. Rosenthal,Dennis G. Maki,Camila Rodrigues,Carlos Álvarez-Moreno,Hakan Leblebicioglu,Martha Sobreyra-Oropeza,Regina Berba,Naoufel Madani,Eduardo A. Medeiros,Luis E. Cuéllar,Zan Mitrev,Lourdes Dueñas,Humberto Guanche-Garcell,Trudell Mapp,Souha S. Kanj,Rosalía Fernández-Hidalgo
Infection Control & Hospital Epidemiology. 2010; 31(12): 1264
[Pubmed] | [DOI]
10 International Nosocomial Infection Control Consortium (INICC) report, data summary for 2003-2008, issued June 2009
Victor D. Rosenthal,Dennis G. Maki,Silom Jamulitrat,Eduardo A. Medeiros,Subhash Kumar Todi,David Yepes Gomez,Hakan Leblebicioglu,Ilham Abu Khader,María Guadalupe Miranda Novales,Regina Berba,Fernando Martín Ramírez Wong,Amina Barkat,Osiel Requejo Pino,Lourdes Dueñas,Zan Mitrev,Hu Bijie,Vaidotas Gurskis,S.S. Kanj,Trudell Mapp,Rosalía Fernández Hidalgo,Nejla Ben Jaballah,Lul Raka,Achilleas Gikas,Altaf Ahmed,Le Thi Anh Thu,María Eugenia Guzmán Siritt
American Journal of Infection Control. 2010; 38(2): 95
[Pubmed] | [DOI]
11 International Nosocomial Infection Control Consortium (INICC) report, data summary for 2003-2008, issued June 2009
Rosenthal, V.D., Maki, D.G., Jamulitrat, S., Medeiros, E.A., Todi, S.K., Gomez, D.Y., Leblebicioglu, H., Guzmán Siritt, M.E.
American Journal of Infection Control. 2010; 38(2): 95-104e2
[Pubmed]
12 Bacterial Contamination of Anaesthetists Hands, Personal Mobile Phones and Wrist Watches used during Theatre Sessions
Gunasekara, T. and Kudavidanage, BP and Peelawattage, MK and Meedin, F. and Guruge, LD and Nanayakkara, G. and Nanayakkara, M. and Fernando, SSN
Sri Lankan Journal of Anaesthesiology. 2009; 17(1): 11
[Pubmed]
13 Device-associated nosocomial infections in limited-resources countries: Findings of the International Nosocomial Infection Control Consortium (INICC).
Rosenthal, V.D. and CIC, M.S.
AJIC: American Journal of Infection Control. 2008; 36(10): S171e7
[Pubmed]
14 Device-associated nosocomial infections in limited-resources countries: Findings of the International Nosocomial Infection Control Consortium (INICC)
Victor D. Rosenthal
American Journal of Infection Control. 2008; 36(10): S171.e7
[Pubmed] | [DOI]



 

Top